LncRNA TTN-AS1 Promotes Migration, Invasion, and Epithelial Mesenchymal Transition of Lung Adenocarcinoma Via Sponging MiR-142-5p to Regulate CDK5

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2019 Aug 1

PMID 31363080

Citations 67

Authors

Yunlong Jia

Yuqing Duan

Tianxu Liu

Xuexiao Wang

Wei Lv

Mengjie Wang

Jiali Wang

Lihua Liu

Affiliations

Soon will be listed here.

Abstract

Emerging evidence suggests that long noncoding RNA (lncRNA) plays pivotal roles in regulating various biological process in human cancers. Titin-antisense RNA1 (TTN-AS1) has been regarded as a tumor promoting lncRNA in numerous cancers. However, the clinical significance and biological function of TTN-AS1 in lung adenocarcinoma (LUAD) remain unclear. In the present study, we revealed that the expression of TTN-AS1 was upregulated in LUAD tissues and cell lines. High TTN-AS1 expression was associated with TNM stage and lymph node metastasis of LUAD patients. In addition, high expression of TTN-AS1 was correlated with poor postoperative prognosis of LUAD patients. Knockdown of TTN-AS1 significantly inhibited the growth, proliferation, migration, and invasion ability of LUAD cells in vitro. Then, by using bioinformation analysis and luciferase reporter experiment, we identified that TTN-AS1 could function as a competing endogenous RNA (ceRNA) by sponging miR-142-5p to regulate the expression of cyclin-dependent kinase 5 (CDK5) in LUAD. Since CDK5 is a key regulator in the process of epithelial mesenchymal transition (EMT), we detected the expression of EMT-related proteins, consequently, EMT was suppressed by knockdown of TTN-AS1 while this phenomenon was rescued by miR-142-5p inhibitor. Taken above, our study revealed that TTN-AS1 played an important role in LUAD progression. TTN-AS1/miR-142-5p/CDK5 regulatory axis may serve as a novel therapeutic target in the treatment of LUAD.

Citing Articles

Non-Coding RNAs in Cancer: Structure, Function, and Clinical Application.

Marton E, Varga A, Domoszlai D, Buglyo G, Balazs A, Penyige A Cancers (Basel). 2025; 17(4).

PMID: 40002172 PMC: 11853212. DOI: 10.3390/cancers17040579.

Attenuated titin protein expression is associated with advanced stages of ovarian cancer.

Sharma H, Aujla J, Nawaz A, Khasawneh T, Alvero A, Morris R Mol Ther Oncol. 2025; 33(1):200932.

PMID: 39944242 PMC: 11815674. DOI: 10.1016/j.omton.2025.200932.

Identification of exosomal ceRNA networks as prognostic markers in clear cell renal cell carcinoma.

Zhu T, Fu H, Wang Z, Guo S, Zhang S Medicine (Baltimore). 2024; 103(43):e40167.

PMID: 39470474 PMC: 11521039. DOI: 10.1097/MD.0000000000040167.

Impact of microRNA variants on PI3K/AKT signaling in triple-negative breast cancer: comprehensive review.

Mehrtabar E, Khalaji A, Pandeh M, Farhoudian A, Shafiee N, Shafiee A Med Oncol. 2024; 41(9):222.

PMID: 39120634 DOI: 10.1007/s12032-024-02469-4.

Differential expression and clinical significance of long non-coding RNAs in the development and progression of lung adenocarcinoma.

Wei H, Zhang S, Lin X, Fang R, Li L Front Oncol. 2024; 14:1411672.

PMID: 38912059 PMC: 11190727. DOI: 10.3389/fonc.2024.1411672.

References

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Li X, Chen W, Jin Y, Xue R, Su J, Mu Z . miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes. Biochem Pharmacol. 2019; 161:98-112. DOI: 10.1016/j.bcp.2019.01.009. View

Nie W, Ge H, Yang X, Sun X, Huang H, Tao X . LncRNA-UCA1 exerts oncogenic functions in non-small cell lung cancer by targeting miR-193a-3p. Cancer Lett. 2015; 371(1):99-106. DOI: 10.1016/j.canlet.2015.11.024. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

Wang Z, Liu Z, Fang X, Yang H . MiR-142-5p Suppresses Tumorigenesis by Targeting PIK3CA in Non-Small Cell Lung Cancer. Cell Physiol Biochem. 2017; 43(6):2505-2515. DOI: 10.1159/000484459. View

Sun S, Zhou X, Huang Y, Kong L, Mei M, Guo W . Targeting STAT3/miR-21 axis inhibits epithelial-mesenchymal transition via regulating CDK5 in head and neck squamous cell carcinoma. Mol Cancer. 2015; 14:213. PMC: 4687320. DOI: 10.1186/s12943-015-0487-x. View

De Craene B, Berx G . Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013; 13(2):97-110. DOI: 10.1038/nrc3447. View

Cheng D, Li J, Zhang L, Hu L . miR-142-5p suppresses proliferation and promotes apoptosis of human osteosarcoma cell line, HOS, by targeting PLA2G16 through the ERK1/2 signaling pathway. Oncol Lett. 2019; 17(1):1363-1371. PMC: 6312951. DOI: 10.3892/ol.2018.9712. View

Seo H, Kim J, Bae S, Soh J, Lee Y . Cdk5-mediated phosphorylation of c-Myc on Ser-62 is essential in transcriptional activation of cyclin B1 by cyclin G1. J Biol Chem. 2008; 283(23):15601-10. PMC: 2414302. DOI: 10.1074/jbc.M800987200. View

10.

Paraskevopoulou M, Vlachos I, Karagkouni D, Georgakilas G, Kanellos I, Vergoulis T . DIANA-LncBase v2: indexing microRNA targets on non-coding transcripts. Nucleic Acids Res. 2015; 44(D1):D231-8. PMC: 4702897. DOI: 10.1093/nar/gkv1270. View

11.

Guttman M, Amit I, Garber M, French C, Lin M, Feldser D . Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009; 458(7235):223-7. PMC: 2754849. DOI: 10.1038/nature07672. View

12.

Falcon T, Freitas M, Mello A, Coutinho L, Alvares-da-Silva M, Matte U . Analysis of the Cancer Genome Atlas Data Reveals Novel Putative ncRNAs Targets in Hepatocellular Carcinoma. Biomed Res Int. 2018; 2018:2864120. PMC: 6038674. DOI: 10.1155/2018/2864120. View

13.

Bian Z, Zhang J, Li M, Feng Y, Wang X, Zhang J . LncRNA-FEZF1-AS1 Promotes Tumor Proliferation and Metastasis in Colorectal Cancer by Regulating PKM2 Signaling. Clin Cancer Res. 2018; 24(19):4808-4819. DOI: 10.1158/1078-0432.CCR-17-2967. View

14.

Katsushima K, Natsume A, Ohka F, Shinjo K, Hatanaka A, Ichimura N . Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment. Nat Commun. 2016; 7:13616. PMC: 5150648. DOI: 10.1038/ncomms13616. View

15.

Wang J, Jia Y, Zhao S, Zhang X, Wang X, Han X . BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer. Oncogene. 2017; 36(45):6235-6243. DOI: 10.1038/onc.2017.217. View

16.

Dorand R, Nthale J, Myers J, Barkauskas D, Avril S, Chirieleison S . Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. Science. 2016; 353(6297):399-403. PMC: 5051664. DOI: 10.1126/science.aae0477. View

17.

Jia Y, Wang H, Wang Y, Wang T, Wang M, Ma M . Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients. Int J Cancer. 2015; 137(5):1095-106. DOI: 10.1002/ijc.29481. View

18.

Herzog J, Ehrlich S, Pfitzer L, Liebl J, Frohlich T, Arnold G . Cyclin-dependent kinase 5 stabilizes hypoxia-inducible factor-1α: a novel approach for inhibiting angiogenesis in hepatocellular carcinoma. Oncotarget. 2016; 7(19):27108-21. PMC: 5053636. DOI: 10.18632/oncotarget.8342. View

19.

Takeyama Y, Sato M, Horio M, Hase T, Yoshida K, Yokoyama T . Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells. Cancer Lett. 2010; 296(2):216-24. PMC: 3110825. DOI: 10.1016/j.canlet.2010.04.008. View

20.

Mercer T, Dinger M, Mattick J . Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009; 10(3):155-9. DOI: 10.1038/nrg2521. View